PE20221723A1 - Anticuerpos contra la integrina alfa 11 beta 1 - Google Patents

Anticuerpos contra la integrina alfa 11 beta 1

Info

Publication number
PE20221723A1
PE20221723A1 PE2022001106A PE2022001106A PE20221723A1 PE 20221723 A1 PE20221723 A1 PE 20221723A1 PE 2022001106 A PE2022001106 A PE 2022001106A PE 2022001106 A PE2022001106 A PE 2022001106A PE 20221723 A1 PE20221723 A1 PE 20221723A1
Authority
PE
Peru
Prior art keywords
beta
integrin alpha
antibodies against
antibodies
against integrin
Prior art date
Application number
PE2022001106A
Other languages
English (en)
Inventor
Jr Christopher Beneduce
Iii James W Meador
Elma Kurtagic
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of PE20221723A1 publication Critical patent/PE20221723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta referida a anticuerpos anti-integrina alfa 11 beta 1 (?11?1) que comprenden una secuencia de aminoacidos seleccionada de un grupo que consiste en SEQ ID NO: 103-435. Asimismo, se describe el metodo de produccion que comprende cultivar una celula huesped o vector, cuyo acido nucleico presenta la secuencia SEQ ID NO: 1-102, ademas que los anticuerpos reclamados tienen aplicacion en el tratamiento de trastornos fibroticos como la Fibrosis Pulmonar Idiopatica (FPI) y enfermedades cancerigenas, entre otros.
PE2022001106A 2019-12-20 2020-12-18 Anticuerpos contra la integrina alfa 11 beta 1 PE20221723A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21
PCT/US2020/066107 WO2021127500A1 (en) 2019-12-20 2020-12-18 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
PE20221723A1 true PE20221723A1 (es) 2022-11-04

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001106A PE20221723A1 (es) 2019-12-20 2020-12-18 Anticuerpos contra la integrina alfa 11 beta 1

Country Status (17)

Country Link
US (1) US20230050972A1 (es)
EP (1) EP4076525A4 (es)
JP (1) JP2023508286A (es)
KR (1) KR20220123013A (es)
CN (1) CN115135342A (es)
AU (1) AU2020407124A1 (es)
BR (1) BR112022012093A2 (es)
CA (1) CA3165386A1 (es)
CL (1) CL2022001673A1 (es)
CO (1) CO2022010204A2 (es)
CR (1) CR20220288A (es)
DO (1) DOP2022000129A (es)
EC (1) ECSP22056627A (es)
IL (1) IL294047A (es)
MX (1) MX2022007521A (es)
PE (1) PE20221723A1 (es)
WO (1) WO2021127500A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505790A (ja) * 2020-12-18 2024-02-08 モメンタ ファーマシューティカルズ インコーポレイテッド インテグリンアルファ１１ベータ１に対する抗体
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2023250415A2 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
CA2709411A1 (en) * 2006-12-18 2008-06-26 Cartela R&D Ab Binding agents to the integrin alpha-11 subunit, and uses thereof
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
WO2019168176A1 (ja) * 2018-03-01 2019-09-06 国立大学法人広島大学 抗インテグリンα１１モノクローナル抗体、およびその利用

Also Published As

Publication number Publication date
CO2022010204A2 (es) 2022-10-21
AU2020407124A1 (en) 2022-07-21
CN115135342A (zh) 2022-09-30
IL294047A (en) 2022-08-01
US20230050972A1 (en) 2023-02-16
MX2022007521A (es) 2022-07-19
ECSP22056627A (es) 2022-11-30
WO2021127500A1 (en) 2021-06-24
EP4076525A4 (en) 2024-05-01
CR20220288A (es) 2022-10-07
JP2023508286A (ja) 2023-03-02
KR20220123013A (ko) 2022-09-05
CL2022001673A1 (es) 2023-02-03
WO2021127500A9 (en) 2021-07-29
BR112022012093A2 (pt) 2022-08-30
EP4076525A1 (en) 2022-10-26
CA3165386A1 (en) 2021-06-24
DOP2022000129A (es) 2022-10-31

Similar Documents

Publication Publication Date Title
PE20221723A1 (es) Anticuerpos contra la integrina alfa 11 beta 1
PH12019501557A1 (en) Bacillus isolates and uses thereof
JP2013078334A5 (es)
TR201820102T4 (tr) Fabri hastalığı gen tedavisi.
PH12019500626A1 (en) Aav treatment of huntington's disease
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
WO2016201301A8 (en) Complement component c5 irna compositions and methods of use thereof
WO2017178883A3 (en) Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
BR112017007932A2 (pt) proteínas inseticidas e métodos para uso das mesmas
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA201692494A1 (ru) Композиции, содержащие липохитоолигосахарид и микроорганизм для усиления роста растения
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
WO2019023034A3 (en) EFFICIENT PRODUCTION OF PICHIA YEASTS AND USE THEREOF TO IMPROVE PLANT AND ANIMAL HEALTH
JP2018507204A5 (es)
CR20220205A (es) INHIBICIÓN DE INTEGRINA a4ß7 HUMANA
AR090636A1 (es) Mutacion del motivo ear de polipeptidos de hd-zip de clase ii
MX2021010264A (es) Formulaciones estables de proteina.
MX2020012332A (es) Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.
MY187334A (en) Xylanase
CO6990667A2 (es) Defensa superior de soja conta plagas
PE20130557A1 (es) Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion
EP3950939A3 (en) Lipase variants and polynucleotides encoding same
AR083445A1 (es) siARN CONTRA LA FIBROSIS
BR112018010225A2 (pt) peptídeos e sua utilização no tratamento do cabelo